A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease

A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease

Total kidney volume (TKV) is a promising imaging biomarker for tracking and predicting the natural history of patients with autosomal dominant polycystic kidney disease. Methods: A drug development tool was developed by linking longitudinal TKV measurements to the probability of a 30% decline of est...

Full description

Bibliographic Details
Main Authors: Ronald D. Perrone, Mohamad-Samer Mouksassi, Klaus Romero, Frank S. Czerwiec, Arlene B. Chapman, Berenice Y. Gitomer, Vicente E. Torres, Dana C. Miskulin, Steve Broadbent, Jean F. Marier
Format: Article
Language:English
Published: Elsevier 2017-05-01
Series:Kidney International Reports
Subjects:
end-stage renal disease
renal function decline
total kidney volume
trial enrichment
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024917300426

Internet

http://www.sciencedirect.com/science/article/pii/S2468024917300426

Similar Items